Mainz Biomed (NASDAQ:MYNZ – Free Report) had its target price reduced by HC Wainwright from $9.00 to $5.00 in a report issued on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2023 earnings at ($0.31) EPS, FY2023 earnings at ($1.67) […]
Mainz Biomed (NASDAQ:MYNZ – Free Report) – HC Wainwright upped their FY2023 earnings per share estimates for shares of Mainz Biomed in a report issued on Monday, November 20th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($1.67) per share for the year, up from their prior forecast of ($1.91). HC […]
Mainz Biomed (NASDAQ:MYNZ – Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 77,800 shares, a decrease of 29.2% from the October 15th total of 109,900 shares. Currently, 0.7% of the shares of the stock are short sold. Based on […]